An ultrasound applicator for endoluminal thermal therapy of pancreatic tumors has been introduced and evaluated through acoustic/biothermal simulations and ex vivo experimental investigations. Endoluminal therapeutic ultrasound constitutes a minimally invasive conformal therapy and is compatible with ultrasound or MR-based image guidance. The applicator would be placed in the stomach or duodenal lumen, and sonication would be performed through the luminal wall into the tumor, with concurrent water cooling of the wall tissue to prevent its thermal injury. A finite-element (FEM) 3D acoustic and biothermal model was implemented for theoretical analysis of the approach. Parametric studies over transducer geometries and frequencies revealed that operating frequencies within 1-3 MHz maximize penetration depth and lesion volume while sparing damage to the luminal wall. Patient-specific FEM models of pancreatic head tumors were generated and used to assess the feasibility of performing endoluminal ultrasound thermal ablation and hyperthermia of pancreatic tumors. Results indicated over 80% of the volume of small tumors (~2 cm diameter) within 35 mm of the duodenum could be safely ablated in under 30 minutes or elevated to hyperthermic temperatures at steadystate. Approximately 60% of a large tumor (~5 cm diameter) model could be safely ablated by considering multiple positions of the applicator along the length of the duodenum to increase coverage. Prototype applicators containing two 3.2 MHz planar transducers were fabricated and evaluated in ex vivo porcine carcass heating experiments under MR temperature imaging (MRTI) guidance. The applicator was positioned in the stomach adjacent to the pancreas, and sonications were performed for 10 min at 5 W/cm 2 applied intensity. MRTI indicated over 40⁰C temperature rise in pancreatic tissue with heating penetration extending 3 cm from the luminal wall.
INTRODUCTION
Pancreatic cancer is responsible for the 4 th highest number of cancer-related mortalities in the United States, and has a 5-year survival of only 4%. 1 Surgical resection is currently the only potentially curative treatment option, but cannot be performed in over 80% of patients due to the advanced stage of their disease at clinical presentation. 1 For these advanced-stage patients, clinical treatment goals are to prolong survival and alleviate pain and other symptoms. Chemotherapy with or without adjuvant radiation therapy are standard treatment regiments, but have minor palliative and survival benefit. 2 Thermal ablation has been demonstrated to provide palliative relief to patients with advanced pancreatic cancer through denervation and tumor debulking mechanisms. 3, 4 It may also extend survival in patients with early-stage and localized disease, potentially serving as an alternative to invasive major surgery. Many ablative modalities, including radiofrequency ablation, microwave ablation, cryoablation, high-intensity focused ultrasound (HIFU), photodynamic therapy, and electroporation are currently being investigated and clinically evaluated for treatment of pancreatic cancer. 3 Apart from HIFU, these applied techniques are all percutaneous or interstitial. Both means are highly invasive and difficult to safely perform in the pancreas due to the risk of inducing pancreatitis and the close proximity of sensitive bowel tissue and vasculature. While HIFU can be applied completely non-invasively, its application is limited due to long treatment times and the challenging delivery of the acoustic energy into the tumor. It is encumbered both by the proximity of bowel gas, which limits the acoustic window, and respiratory motion. 4 There is also interest in developing hyperthermia treatments for advanced pancreatic cancer. Hyperthermia has been clinically demonstrated to enhance the therapeutic benefit of chemotherapy and radiation therapy for many other cancer models, and may increase the drug delivery of thermally sensitive liposomes into desmoplastic pancreatic tumors. 5, 6 Thermal therapy and hyperthermia treatments of pancreatic cancer could be performed in a minimally invasive manner using an endoluminal ultrasound applicator, as conceptualized in Figure 1 . This applicator would be inserted into the esophagus orally and manipulated to the stomach or duodenal lumen adjacent to the tumor-bearing region in the pancreas. Sonication would be directed into the tumor through the gastrointestinal (GI) luminal wall, and cooling of the active transducers and adjacent wall tissue would be achieved by circulating water through a balloon covering the transducers. Ultrasound confers many advantages over other modalities, including directionality and high spatial control over the energy deposition through selecting the appropriate transducer geometry and operating frequency. This approach is also inherently compatible with image-guidance, including ultrasound or MR, allowing a means of providing direct treatment monitoring and feedback control during the course of the therapy. In order to validate this treatment strategy, a theoretical evaluation was performed using 3D acoustic and biothermal modeling. Parametric studies for ablation treatments using a generalized anatomical model were used to identify favorable design parameters of the applicator transducers. These results were used for modeling thermal ablation and hyperthermia treatments in patientspecific models of pancreatic cancer to evaluate feasibility and safety of the approach. Preliminary prototype devices were fabricated and experimentally evaluated in ex vivo porcine carcass studies using MR guidance and MR temperature imaging (MRTI). 
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CONCLUSIONS
Theoretical studies illustrate the feasibility of performing endoluminal ultrasound thermal therapy of pancreatic head tumors while preventing thermal injury to sensitive structures. Parametric studies over transducer geometry and frequency indicate that operating frequencies in the range of 1-3 MHz maximize penetration and coagulation volume for ablation treatments while mitigating luminal heating. Thermal ablation modeling in patient-specific models of small tumors extending 35 mm from the luminal wall have demonstrated capability of debulking large portions of the tumor in short (< 30 min) treatment times without significant damage to non-tumor tissues. Elevation of large portion of these tumors above 40⁰C for hyperthermia was also demonstrated to be feasible. The larger tumor (~5 cm diameter) model required translation of the applicator during treatment for ablation of appreciable volumes of the tumor, and would be an unlikely candidate for hyperthermia using this approach due to limited coverage at a single position. Prototype endoluminal applicators were fabricated and contained two planar 1 cm square transducers operating at 3.2 MHz. These applicators were characterized in ex vivo porcine carcass heating experiments with MRTI guidance. The prototype applicators could be positioned in the stomach of the porcine adjacent to the pancreas, and exhibited sufficient heating of pancreatic tissue for ablative purposes, with a heating penetration of approximately 3 cm.
